The global Vaccines Market, valued at US$59.52 billion in 2024, stood at US$50.46 billion in 2025 and is projected to advance at a ...

We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Merck & Co., Inc. stands third among them. Merck & Co., Inc. (NYSE:MRK), a global leader in pharmaceuticals ...

Coupled with headwinds in China, Merck is also seeing lower demand for Gardasil in Japan. Sales are expected to remain weak in Japan in the second half of 2025. Our estimates for Gardasil sales ...

Real-world study data showed that the monoclonal antibody nirsevimab was highly effective at preventing severe respiratory ...

ACOG released updated clinical guidance on vaccination for COVID-19, respiratory syncytial virus and influenza during ...

The Manitoba government plans on updating its RSV immunization program this fall, but the province is not committing to following the majority of Canada in extending the preventative treatment to ...

Background: Respiratory Syncytial Virus (RSV) poses a major health threat to older adults, pregnant women, and high-risk populations. We systematically evaluated the efficacy, immunogenicity, and ...

Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

Merck & Co, a leading healthcare giant, has seen its shares plummet by 30% over the past year. Investors generally view the healthcare sector as a safe bet during economic downturns. The industry not ...